Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Other Non-Current Liabilities (2020 - 2025)

Mirum Pharmaceuticals has reported Other Non-Current Liabilities over the past 6 years, most recently at $5.0 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $5.0 million for Q4 2025, up 99.72% from a year ago — trailing twelve months through Dec 2025 was $5.0 million (up 99.72% YoY), and the annual figure for FY2025 was $5.0 million, up 99.72%.
  • Other Non-Current Liabilities for Q4 2025 was $5.0 million at Mirum Pharmaceuticals, down from $16.0 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for MIRM hit a ceiling of $138.0 million in Q3 2022 and a floor of $10000.0 in Q1 2022.
  • Median Other Non-Current Liabilities over the past 5 years was $4.1 million (2022), compared with a mean of $21.4 million.
  • Biggest five-year swings in Other Non-Current Liabilities: surged 420823.33% in 2021 and later tumbled 99.98% in 2022.
  • Mirum Pharmaceuticals' Other Non-Current Liabilities stood at $2.0 million in 2021, then tumbled by 45.39% to $1.1 million in 2022, then surged by 253.12% to $3.8 million in 2023, then tumbled by 34.81% to $2.5 million in 2024, then skyrocketed by 99.72% to $5.0 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $5.0 million (Q4 2025), $16.0 million (Q3 2025), and $9.1 million (Q2 2025) per Business Quant data.